NO20084927L - Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem - Google Patents

Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem

Info

Publication number
NO20084927L
NO20084927L NO20084927A NO20084927A NO20084927L NO 20084927 L NO20084927 L NO 20084927L NO 20084927 A NO20084927 A NO 20084927A NO 20084927 A NO20084927 A NO 20084927A NO 20084927 L NO20084927 L NO 20084927L
Authority
NO
Norway
Prior art keywords
phosphoinositide
pharmaceutical compositions
compositions containing
kinase inhibitor
inhibitor compounds
Prior art date
Application number
NO20084927A
Other languages
English (en)
Norwegian (no)
Inventor
Vickie Hsiao-Wei Tsui
Janet Gunzner
Georgette Castanedo
Shumei Wang
Kimberly Malesky
Alan Olivero
Jennafer Dotson
Richard Goldsmith
Tim Heffron
Simon Mathieu
Daniel P Sutherlin
Christian Weismann
Zhu Bing-Yan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38561741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084927(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20084927L publication Critical patent/NO20084927L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
NO20084927A 2006-04-26 2008-11-25 Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem NO20084927L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79504706P 2006-04-26 2006-04-26
PCT/US2007/009880 WO2007127183A1 (en) 2006-04-26 2007-04-24 Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
NO20084927L true NO20084927L (no) 2009-01-23

Family

ID=38561741

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084927A NO20084927L (no) 2006-04-26 2008-11-25 Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem

Country Status (17)

Country Link
US (2) US7846929B2 (https=)
EP (1) EP2046799B1 (https=)
JP (1) JP5291616B2 (https=)
KR (1) KR101402474B1 (https=)
CN (1) CN101511840A (https=)
AR (1) AR060632A1 (https=)
AU (1) AU2007243466B2 (https=)
BR (1) BRPI0710908A2 (https=)
CA (1) CA2650295C (https=)
CL (1) CL2007001166A1 (https=)
IL (1) IL194761A0 (https=)
MX (1) MX2008013583A (https=)
NO (1) NO20084927L (https=)
RU (1) RU2437888C2 (https=)
TW (1) TW200801012A (https=)
WO (1) WO2007127183A1 (https=)
ZA (1) ZA200810023B (https=)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693804B1 (en) * 1996-09-04 2009-11-11 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing and rights management
CN101511840A (zh) 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
TWI498332B (zh) * 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
ES2571028T3 (es) * 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US7893060B2 (en) * 2007-06-12 2011-02-22 F. Hoffmann-La Roche Ag Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042607A1 (en) * 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
CN101835779B (zh) * 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
AU2009246053B2 (en) 2008-05-14 2014-07-24 Agriculture Victoria Services Pty Ltd. Use of angiogenin or angiogenin agonists for treating diseases and disorders
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック， インコーポレイテッド プリンｐｉ３ｋ阻害剤化合物および使用方法
AR073354A1 (es) * 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
NZ592748A (en) 2008-10-17 2013-01-25 Akaal Pharma Pty Ltd 2-Amino-(oxadiazol-3-yl)-benzofuran derivatives and their use as S1P receptor modulators
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
US8586582B2 (en) 2008-11-11 2013-11-19 Xcovery Holding Company, Llc PI3K/mTOR kinase inhibitors
US8653098B2 (en) 2008-11-20 2014-02-18 Genentech, Inc. Pyrazolopyridine PI3K inhibitor compounds and methods of use
SI2373640T1 (sl) 2009-01-08 2014-11-28 Merck Patent Gmbh Nove polimorfne oblike hidrokloridne soli 3-(1-(3-(5-(1-metil-piperidin-4ilmetoksi)-pirimidin-2-il)-benzil)-6- okso-1,6-dihidro-piridazin-3-il)-benzonitrila in postopki proizvodnje le-teh
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
CN102369011A (zh) 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
ES2665277T3 (es) * 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
CN102361878A (zh) 2009-03-24 2012-02-22 住友化学株式会社 用于制备硼酸酯化合物的方法
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CA2772371A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN102459272B (zh) * 2009-05-27 2014-08-06 健泰科生物技术公司 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
SG176959A1 (en) * 2009-06-24 2012-01-30 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011017520A1 (en) * 2009-08-05 2011-02-10 Wake Forest University Health Sciences Compositions and methods for inducing apoptosis in prostate cancer cells
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
IN2012DN01325A (https=) * 2009-08-20 2015-06-05 Karus Therapeutics Ltd
EP2475375A4 (en) * 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF
EP2475367A1 (en) * 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
ES2558742T3 (es) 2009-09-28 2016-02-08 F. Hoffmann-La Roche Ag Compuestos inhibidores de PI3K de benzoxepina y métodos de uso
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PH12012500901A1 (en) 2009-11-05 2016-08-05 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
CN102712642B (zh) * 2009-11-12 2015-08-12 霍夫曼-拉罗奇有限公司 N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法
WO2011058027A2 (en) * 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
MX2012009059A (es) 2010-02-22 2012-09-07 Hoffmann La Roche Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
JP5555378B2 (ja) 2010-07-14 2014-07-23 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋｐ１１０デルタに選択的なプリン化合物とその使用の方法
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
CA2825028A1 (en) 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
HRP20190128T1 (hr) 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. Novi spojevi kao modulatori protein kinaza
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
KR101255939B1 (ko) * 2011-05-31 2013-04-23 동화약품주식회사 4-(1ｈ-인다졸-6-일아미노)-ｎ-아이소프로필-2-(메틸티오)피리미딘-5-카르복스아미드 화합물 또는 이의 약학적으로 허용가능한 염을 포함하는 당뇨병 예방 또는 치료용 조성물
CA2849331A1 (en) * 2011-10-13 2013-04-18 Genentech, Inc. Treatment of pharmacological-induced hypochlorhydria
HK1202333A1 (en) * 2011-11-11 2015-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CN102643272B (zh) * 2011-12-30 2015-03-11 沈阳药科大学 新的噻吩并[3,2-d]嘧啶类化合物
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN103467482B (zh) 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
DK2838533T3 (da) 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
CA2872002C (en) * 2012-05-07 2019-01-15 Masayuki Isaji Pyrazole derivative and use thereof for medical purposes
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CN109970742A (zh) 2012-07-04 2019-07-05 理森制药股份公司 选择性PI3Kδ抑制剂
MX361157B (es) * 2012-08-30 2018-11-28 Hoffmann La Roche Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso.
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
JP6329958B2 (ja) 2012-11-07 2018-05-23 カルス セラピューティクス リミテッド 新規ヒストンデアセチラーゼインヒビターおよび治療におけるその使用
EP2984088B1 (en) * 2013-04-12 2019-03-20 Asana BioSciences, LLC Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
NZ714283A (en) 2013-05-10 2020-04-24 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
NZ718487A (en) 2013-10-16 2020-01-31 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
EP3102569A1 (en) 2014-02-06 2016-12-14 AbbVie Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
CN118059093A (zh) 2015-03-08 2024-05-24 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
US20180057505A1 (en) * 2015-03-20 2018-03-01 Vertex Pharmaceuticals Incorporated Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
ES2733505T3 (es) * 2015-03-30 2019-11-29 Daiichi Sankyo Co Ltd Derivados de 6-morfolinil-2-pirazolil-9H-purina y su uso como inhibidores PI3K
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
HK1249866A1 (zh) 2015-06-29 2018-11-16 豪夫迈‧罗氏有限公司 用他塞利昔布进行治疗的方法
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
WO2017197151A1 (en) 2016-05-11 2017-11-16 Emory University Phosphotidylinositol 3-kinase inhibitors
MY199070A (en) 2016-06-01 2023-10-12 Bayer Pharma AG Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
WO2018057588A1 (en) * 2016-09-21 2018-03-29 Vertex Pharmaceuticals Incorporated Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
CN109796465B (zh) * 2017-11-16 2020-07-14 华中科技大学同济医学院附属协和医院 靶向pet显像化合物、包含该化合物的显象剂及其制备方法和用途
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CA3154278A1 (en) * 2018-10-12 2020-04-16 Corey Hopkins Phosphodiesterase inhibitors
CN120463721A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
EP4161519A4 (en) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
JP7675182B2 (ja) * 2020-11-10 2025-05-12 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
EP4303216A1 (en) * 2021-03-03 2024-01-10 Genfleet Therapeutics (Shanghai) Inc. Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof
US20240226126A1 (en) * 2021-06-16 2024-07-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions for treatment of psoriasis
WO2022268025A1 (zh) * 2021-06-22 2022-12-29 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
US20250042914A1 (en) * 2021-09-30 2025-02-06 Hanmi Pharm. Co., Ltd. Pikfyve kinase inhibitor
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用
CN118488947A (zh) * 2022-01-04 2024-08-13 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途
CN114539293B (zh) * 2022-02-24 2023-09-22 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用
AR129299A1 (es) 2022-05-11 2024-08-07 Foghorn Therapeutics Inc Compuestos para modular complejos de factores asociados a brg1 o brm (baf)
CN117164590B (zh) * 2022-05-25 2026-03-17 沈阳药科大学 稠合嘧啶类衍生物及其应用
TW202432114A (zh) * 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (https=) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
US6894055B2 (en) * 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
AU2002349912A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2004017950A2 (en) * 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CN101511840A (zh) 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
EP2475375A4 (en) * 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF

Also Published As

Publication number Publication date
US20080039459A1 (en) 2008-02-14
RU2437888C2 (ru) 2011-12-27
CA2650295C (en) 2015-12-29
JP5291616B2 (ja) 2013-09-18
WO2007127183A1 (en) 2007-11-08
US8450315B2 (en) 2013-05-28
KR101402474B1 (ko) 2014-06-19
CA2650295A1 (en) 2007-11-08
US20110105464A1 (en) 2011-05-05
AR060632A1 (es) 2008-07-02
US7846929B2 (en) 2010-12-07
IL194761A0 (en) 2009-08-03
CN101511840A (zh) 2009-08-19
EP2046799B1 (en) 2017-07-19
JP2009535335A (ja) 2009-10-01
EP2046799A1 (en) 2009-04-15
AU2007243466B2 (en) 2012-01-19
CL2007001166A1 (es) 2008-01-25
KR20090024682A (ko) 2009-03-09
AU2007243466A1 (en) 2007-11-08
BRPI0710908A2 (pt) 2012-06-26
ZA200810023B (en) 2009-08-26
TW200801012A (en) 2008-01-01
MX2008013583A (es) 2008-10-31
RU2008145662A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
NO20084927L (no) Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem
NO20084928L (no) Farmasoytiske sammensetninger
MX2010010659A (es) Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
PH12012500608A1 (en) Benzoxepin pi3k inhibitor compounds and methods of use
MX2010002543A (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
PH12013501779A1 (en) Pyrrolopyridines as kinase inhibitors
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
MX2008011220A (es) Compuestos de pirazol heterobiciclicos y metodos de uso.
AU2009312464A8 (en) Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
NO20092566L (no) Fosfoinositid 3-kinaseinhibitorforbmdelser og fremgangsmater for anvendelse
NO20092565L (no) Fosfoinositid 3-kinaseinhibitorforbmdelser og fremgangsmater for anvendelse
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
WO2007146824A3 (en) Quinoline compounds and methods of use
WO2007027855A3 (en) Raf inhibitor compounds and methods of use thereof
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
WO2006125101A3 (en) Raf inhibitor compounds and methods of use thereof
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
WO2011025938A3 (en) Raf inhibitor compounds and methods of use thereof
TW200639163A (en) RAF inhibitor compounds and methods
ECSP10010507A (es) Pirazolo (3, 4-b) piridina inhibidores de raf
BR112013014914A2 (pt) composto, composição farmacêutica, método de tratar câncer em um paciente e uso
UA98946C2 (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application